Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 1, 2014, Pages 77-84.e1

  Bernstein, Jonathan A ^a   Manning, Michael E ^b   Li, Henry ^c   White, Martha V ^d   Baker, James ^e   Lumry, William R ^f   Davis Lorton, Mark A ^g   Jacobson, Kraig W ^h   Gower, Richard G ⁱ   Broom, Colin ^j   Fitts, David ^j   Schranz, Jennifer ^j  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Allergy Asthma and Immunology Associates   (United States)

^c Institute for Asthma and Allergy   (United States)

^d Institute for Asthma and Allergy   (United States)

^e Baker Asthma Allergy and Dermatology   (United States)

^f AARA Research Center   (United States)

^g WINTHROP UNIVERSITY HOSPITAL   (United States)

^h Allergy and Asthma Research Group   (United States)

ⁱ Marycliff Allergy Specialists   (United States)

^j ViroPharma Incorporated   (United States)

more..

Author keywords

Angioedema; C1 esterase inhibitor; C1 INH; Dose escalation; HAE; Hereditary angioedema; Prophylaxis; Thrombotic events; Treatment

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; DRUG ANTIBODY;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; IMMUNOGENICITY; LIGAMENT INJURY; LIMB PAIN; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; NANOFILTRATION; PHASE 4 CLINICAL TRIAL; PROPHYLAXIS; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SPRAIN; THROMBOGENICITY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANGIOEDEMA; C1 ESTERASE INHIBITOR; C1 INH; C1 INH-NF; DOSE ESCALATION; HAE; HEREDITARY ANGIOEDEMA; NANOFILTERED C1 INH (HUMAN); PROPHYLAXIS; THROMBOTIC EVENTS; TREATMENT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1S; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84891663162     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.09.008     Document Type: Article

References (17)

1. Bowen T., Cicardi M., Bork K., Zuraw B., Frank M., Ritchie B., et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008, 100:S30-S40.
2. Nzeako U.C., Frigas E., Tremaine W.J. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001, 161:2417-2429.
3. CINRYZE [package insert] 2012, ViroPharma Incorporated, Exton.
4. CINRYZE [summary of product characteristics] 2012, ViroPharma SPRL, Brussels, Belgium.
5. Zuraw B.L., Busse P.J., White M., Jacobs J., Lumry W., Baker J., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010, 363:513-522.
6. Zuraw B.L., Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012, 125:938.e1-938.e7.
7. Levy J.H., O'Donnell P.S. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006, 15:1077-1090.
8. German Federal Medical Council Drug Commission of the German medical profession: serious thrombogenesis following Berinert HS. Ger Med J 2000, 97. B-864.
9. Horstick G., Berg O., Heimann A., Gotze O., Loos M., Hafner G., et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 2001, 104:3125-3131.
10. Caliezi C., Zeerleder S., Redondo M., Regli B., Rothen H.U., Zurcher-Zenklusen R., et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002, 30:1722-1728.
11. Lazareva N.B., Igonin A.A. Safety and efficacy of purified human C1-esterase inhibitor in the treatment of patients with sepsis [in Russian with English abstract]. Antibiot Khimioter 2009, 54:42-46.
12. Thielmann M., Marggraf G., Neuhauser M., Forkel J., Herold U., Kamler M., et al. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg 2006, 30:285-293.
13. Fattouch K., Bianco G., Speziale G., Sampognaro R., Lavalle C., Guccione F., et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 2007, 32:326-332.
14. Hentjes B., Jankowski M., Vangerow B., Struber M., Anssar M., Leuwer M., et al. C1-esterase-inhibitor levels in patients with and without reperfusion injury following lung transplantation (LTx). Ann Hematol 1997, 74:A157.
15. Gandhi P.K., Gentry W.M., Bottorff M.B. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012, 32:902-909.
16. Zingale L.C., Castelli R., Zanichelli A., Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am 2006, 26:669-690.
17. Cicardi M., Zanichelli A. The acquired deficiency of C1-inhibitor: lymphoproliferation and angioedema. Curr Mol Med 2010, 10:354-360.